Biolimus-eluting stent with biodegradable polymer (Nobori®): an overview of recent clinical results, SORT OUT V and COMPARE II trials

References

• Morice MC, Serruys PW, Sousa J et al. RAVEL study group. Randomized study with the sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346(23), 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cox DA et al. TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350(3), 221–231 (2004).
   PubMed Web of Science ®Google Scholar
• Lemesle G, Maluenda G, Collins SD, Waksman R. Drug-eluting stents: issues of late stent thrombosis. Cardiol. Clin. 28(1), 97–105 (2010).
   PubMedGoogle Scholar
• Lemesle G, Pinto Slottow TL, Waksman R. Very late stent thrombosis after bare-metal stent implantation: case reports and review of the literature. J. Invasive Cardiol. 21(2), E27–32 (2009).
   PubMedGoogle Scholar
• Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369(9562), 667–678 (2007).
   PubMed Web of Science ®Google Scholar
• Jensen LO, Tilsted HH, Thayssen P et al. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention 5(8), 898–905 (2010).
   PubMed Web of Science ®Google Scholar
• Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48(1), 193–202 (2006).
   PubMed Web of Science ®Google Scholar
• Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 120(5), 391–399 (2009).
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, Joner M et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118(11), 1138–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Lüscher TF, Steffel J, Eberli FR et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115(8), 1051–1058 (2007).
   PubMed Web of Science ®Google Scholar
• Hossainy S, Prabhu S. A mathematical model for predicting drug release from a biodurable drug-eluting stent coating. J. Biomed. Mater. Res. A. 87(2), 487–493 (2008).
   PubMed Web of Science ®Google Scholar
• Abizaid A, Costa JRJr. New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems. Circ. Cardiovasc. Interv. 3(4), 384–393 (2010).
   PubMed Web of Science ®Google Scholar
• Ostojic M, Sagic D, Jung R et al. NOBORI PK Investigators. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter. Cardiovasc. Interv. 72(7), 901–908 (2008).
   PubMed Web of Science ®Google Scholar
• Christiansen EH, Jensen LO, Thayssen P et al. Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V investigators. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 381(9867), 661–669 (2013).
   PubMed Web of Science ®Google Scholar
• Smits PC, Hofma S, Togni M et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 381(9867), 651–660 (2013).
   PubMed Web of Science ®Google Scholar
• Danzi GB, Chevalier B, Urban P et al. NOBORI 2 Investigators. Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study. EuroIntervention 8(1), 109–116 (2012).
   PubMed Web of Science ®Google Scholar
• Chevalier B, Silber S, Park SJ et al. NOBORI 1 Clinical Investigators. Randomized comparison of the Nobori biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial – Phase 2. Circ. Cardiovasc. Interv. 2(3), 188–195 (2009).
   PubMed Web of Science ®Google Scholar
• Ostojic M, Sagic D, Beleslin B et al. First clinical comparison of Nobori–biolimus A9 eluting stents with Cypher–sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. EuroIntervention 3(5), 574–579 (2008).
   PubMedGoogle Scholar
• Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372(9644), 1163–1173 (2008).
   PubMed Web of Science ®Google Scholar
• Stefanini GG, Kalesan B, Serruys PW et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 378(9807), 1940–1948 (2011).
   PubMed Web of Science ®Google Scholar